Elixir Medical's Late-Breaking 12-Month Data Demonstrate Sig

DESyne BDS Plus system with site-specific antithrombotic therapeutic (TRx) significantly reduced the risk of TLF versus conventional drug-eluting stent through 12-months

Related Keywords

New Zealand , Sao Paulo , Sãpaulo , Brazil , Paris , France General , France , United States , Alexandran Nowbar , Jamesp Howard , Michael Foley , Kui Hong , Motasim Sirhan , Xiaoqing Li , Liza Chacko , Darrelp Francis , Ochen , Dina Mahdi , Sayan Sen , Alexandre Abizaid , Graham Cole , Rasha Al Lamee , Yuhao Su , Yousif Ahmad , Christopher Kane , Christopher Rajkumar , Centers For Disease , Randomized Controlled Trial , Randomized Clinical Trial , Triple Drug Eluting Coronary Implant , Eluting Coronary Stent System , Disease Facts , Disease Control , Matthew Shun Shin , Percutaneous Coronary Intervention , Myocardial Infarction Stratified , Unstable Coronary Artery Disease , Randomized Controlled Trials , Cardiovascular Quality , Non Cardiac Surgery Early , Percutaneous Coronary ,